Schonfeld Strategic Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.81M	Buy	177,585 +127,764	+256%	+$3.75M	0.03%	505
2025 Q4	$1.81M	Buy	49,821 +35,203	+241%	+$1.41M	0.01%	909
2025 Q3	$554K	Sell	14,618 -238,581	-94%	-$5.16M	﹤0.01%	1647
2025 Q2	$3.43M	Buy	253,199 +35,737	+16%	+$518K	0.02%	719
2025 Q1	$3.45M	Buy	+217,462	New	+$2.5M	0.02%	672
2023 Q4	–	Sell	-192,362	Closed	-$1.83M	–	2081
2023 Q3	$1.83M	Buy	192,362 +75,248	+64%	+$981K	0.01%	856
2023 Q2	$2M	Buy	117,114 +28,266	+32%	+$422K	0.02%	757
2023 Q1	$1.39M	Buy	+88,848	New	+$1.5M	0.01%	811

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Schonfeld Strategic Advisors's MLYS Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Mineralys Therapeutics (MLYS) stake by 256% in Q1 2026, buying an estimated $3.75M and bringing the position to 177,585 shares worth $4.81M. The position accounts for 0.03% of the portfolio, ranked #505.

Schonfeld Strategic Advisors first reported a position in MLYS in Q1 2023 and has held it in 8 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Schonfeld Strategic Advisors held 177,585 shares of Mineralys Therapeutics worth $4.81M as of Q1 2026.
Schonfeld Strategic Advisors bought 127,764 Mineralys Therapeutics shares in Q1 2026, an estimated $3.75M.
Mineralys Therapeutics made up 0.03% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #505 holding.
Schonfeld Strategic Advisors first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 8 quarters since.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.